Zahra Kashi

Zahra Kashi

Auto-generated profile, based on publicly available information

Zahra Kashi

Diabetes Research Center, Mazandaran University of Medical Sciences, Sari, Iran

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
KRKhadijeh Rabiei
Khadijeh Rabiei
MEMohammad Ali Ebrahimzadeh
Mohammad Ali Ebrahimzadeh
MSMajid Saeedi
Majid Saeedi
ABAdele Bahar
Adele Bahar
OAOzra Akha
Ozra Akha
ZKZahra Kashi
Zahra Kashi
We aimed to evaluate the effects of a hydroalcoholic extract of Juglans regia L. leaves on blood glucose level and cardiovascular risk factors in type 2 diabetic patients. In this randomized, double-blind, placebo-controlled, parallel-group (2 arms) clinical trial, 50 diabetic patients were divided into two groups: treatment group (receive the capsules containing 100 mg J. regia leaf extract) and control group (receive the capsules containing placebo, microcrystallin cellulose). Baseline participant data were matched between the two arms of the study. We administered the prepared capsules to the patients twice daily for 8 weeks. Blood glucose level, glycosylated hemoglobin (HbA1c) level, body weight, body mass index, blood pressure, lipid profile, serum insulin, and insulin resistance were compared between the two groups before and after the intervention. P < 0.05 was considered significant. After excluding eleven patients, 20 received J. regia leaf extract and 20 patients received placebo. The J. regia leaf extract did not significantly change the blood glucose and insulin resistance condition. However, in this group, body weight, body mass index, and systolic blood pressure significantly decreased compared with the baseline measurements (P = 0.028, P = 0.030, and P = 0.005, respectively). The lipid profile did not change significantly compared with the baseline measurements. In the control group, postprandial glucose and HbA1c levels significantly decreased after the intervention (P = 0.030 and P = 0.028, respectively). The other variables were not significantly different in this group. At the end of the study, the variables were not significantly different between the two groups. In this double-blind study, 200 mg/d of J. regia leaf extract had no significant effect on blood glucose level and HOMA-IR score in patients with type 2 diabetes. However, the J. regia leaf extract was effective in reducing body weight and blood pressure. An accidental finding of our study was that microcrystalline cellulose, a widely used placebo in clinical trials, led to a reduction in blood glucose level. Iranian Registry of Clinical Trials (IRCT: 138901203180 N2 , 2010/6/6); retrospectively registered.

1 October 2016 in Medicine
Verified
Journal Article
Open access
ABAdeleh Bahar
Adeleh Bahar
ZKZahra Kashi
Zahra Kashi
EDEzzatossadat Daneshpour
Ezzatossadat Daneshpour
OAOzra Akha
Ozra Akha
SAShahram Ala
Shahram Ala
Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evaluate the effects of cabergoline on blood glucose levels in patients with type 2 diabetes mellitus (DM). This study was a double-blind, controlled clinical trial in patients with type 2 DM. The patients received treatments of a placebo (control group; n = 20) or cabergoline 0.5 mg (cabergoline group; n = 20) using the sequential method, once per week for 3 months, while using previously prescribed glucose-lowering drugs. All tests, such as levels of fasting blood glucose, 2-hour post-prandial glucose, complete lipid profile, prolactin, alanine amino transferase, aspartate amino transferase, creatinine, blood urea nitrogen, and serum insulin, and homeostasis model assessment insulin resistance were measured at baseline and at 3-month follow-up. The fasting blood sugar levels were significantly different between placebo and cabergoline groups after 3 months of treatment (P = 0.004). The prolactin levels were significantly different from beginning of the treatment to 6 months later (P = 0.001). In the cabergoline group, there was a significant decrease in glycosylated hemoglobin (HbA1C) levels after 3 months (P = 0.003). Overall, 65%and 45% patients in the cabergoline and control groups, respectively, responded to treatment (HbA1C<7%). Cabergoline may be useful as a long-acting antidiabetic agent in patients with type 2 diabetes mellitus.

17 April 2014 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
AMAbdolkarim Mahrooz
Abdolkarim Mahrooz
HPHassan Parsanasab
Hassan Parsanasab
MHMohammad Bagher Hashemi-soteh
Mohammad Bagher Hashemi-soteh
ZKZahra Kashi
Zahra Kashi
ABAdeleh Bahar
Adeleh Bahar
MMMaliheh Mozayeni
Maliheh Mozayeni

15 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZKZahra Kashi
Zahra Kashi
AMAbdolkarim Mahrooz
Abdolkarim Mahrooz
AKAnvarsadat Kianmehr
Anvarsadat Kianmehr
AAAhad Alizadeh
Ahad Alizadeh
In this study, we investigated whether response to metformin, the most frequently drug for diabetes treatment, influences the therapeutic effects of antilipidemic medication in newly diagnosed patients with type 2 diabetes mellitus (T2DM). A total of 150 patients with T2DM were classified into two groups following 3 months of metformin therapy (1000 mg twice daily): responders (patients showing ≥1% reduction in HbA1c from baseline) and nonresponders (patients showing <1% reduction in HbA1c from baseline). The patients received atorvastatin 20 mg, gemfibrozil 300 mg, or atorvastatin 20 mg and gemfibrozil 300 mg daily. HbA1c and fasting glucose levels were significantly different between baseline and 3 months among responders receiving atorvastatin; however, these differences were not statistically significant in nonresponders. Atherogenic ratios of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol (LDL-C/HDL-C; p = 0.002), total cholesterol to HDL-C (TC/HDL-C; p<0.001) and AIP (the atherogenic index of plasma; p = 0.004) decreased significantly in responders receiving atorvastatin than in nonresponders. Moreover, responders receiving atorvastatin showed a significant increase in HDL-C levels but nonresponders receiving atorvastatin did not (p = 0.007). The multivariate model identified a significant association between metformin response (as the independent variable) and TG, TC, HDL-C and LDL-C (dependent variables; Wilk's λ = 0.927, p = 0.036). Metformin response affects therapeutic outcomes of atorvastatin on atherogenic lipid markers in patients newly diagnosed with T2DM. Metformin has a greater impact on BMI in responders of metformin compared to nonresponders. Adoption of better therapeutic strategies for reducing atherogenic lipid markers may be necessary for metformin nonresponders.

30 March 2013 in Nephro-Urology Monthly
Verified
Journal Article
Open access
PDF file
ABAdeleh Bahar
Adeleh Bahar
AMAtieh Makhlough
Atieh Makhlough
AYAtefe Yousefi
Atefe Yousefi
ZKZahra Kashi
Zahra Kashi
SASaeid Abediankenari
Saeid Abediankenari
Background: Impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) are two prediabetes conditions which have some correlation with macrovascular disorders. The risk of microvascular complications in these groups is not clear. Objectives: The prevalence of albuminuria in subjects with IFG and IGT was evaluated in the present study. Patients and Methods: In this study three groups of subjects were entered (45 subjects in each group): IFG, IGT, and normal glucose tolerance as control. The urine albumin-creatinine ratio was studied in morning spot urine samples to detect microalbuminuria. The subjects were followed up for two years, and blood sugar and urine albumin and glycosylated hemoglobin (HbA1C) were measured every 6 months. Results: The prevalence rate of microalbuminuria was 15.5% in the prediabetic groups, while no one had microalbuminuria in the control group (P = 0.005). The prevalence of microalbuminuria in patients with IFG or IGT was not significantly different (17.8% vs. 13.3%) (P = 0.4). Fourteen subjects (4 in IFG group and 10 in IGT group) developed diabetes mellitus within a 2-year follow-up period (P = 0.1). Thirty six percent of subjects with albuminuria, and twelve percent of subjects without albuminuria progressed to diabetes mellitus during a 2-year follow-up (P = 0.02, odd ratio = 4.1; CI95%, 1.13-15.1). Conclusions: The risk of microalbuminuria in prediabetic subjects is high, and probably prediabetic subjects are at higher risk of progression to diabetes mellitus. We suggest periodically evaluation of albuminuria in prediabetic patients after the diagnosis. Keywords: Glucose Tolerance; Diabetic Nephropathies; Diabetes Mellitus, Type 2

1 April 2015 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
ZKZahra Kashi
Zahra Kashi
PMParisa Masoumi
Parisa Masoumi
AMAbdolkarim Mahrooz
Abdolkarim Mahrooz
MHMohammad Bagher Hashemi-soteh
Mohammad Bagher Hashemi-soteh
ABAdeleh Bahar
Adeleh Bahar
AAAhad Alizadeh
Ahad Alizadeh